32 assets in Myelodysplastic Syndrome With Excess Blasts

Therapeutic assets addressing Myelodysplastic Syndrome With Excess Blasts, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Myelodysplastic Syndrome With Excess Blasts	University of Southern California	P3	BBB (72)
Cyclosporin A Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P2	BB (71)
Fludarabine Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P3	BB (71)
Tacrolimus Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P2	BB (71)
Cyclophosphamide Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P3	BB (70)
Etoposide Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P3	BB (70)
Idarubicin Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P3	BB (70)
Azacitidine Myelodysplastic Syndrome With Excess Blasts	Apollo Therapeutics Ltd	P2	BB (69)
Dexasone Myelodysplastic Syndrome With Excess Blasts	National Cancer Institute (NCI)	P3	BB (69)
Nivestim Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P3	BB (69)
(+)-Vincristine Myelodysplastic Syndrome With Excess Blasts	Roswell Park Cancer Institute	P2	BB (67)
Busulfanum Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P3	BB (66)
Vorinostat Myelodysplastic Syndrome With Excess Blasts	National Cancer Institute (NCI)	P2	B (62)
Melphalan Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P2	B (61)
Clofarabine Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P2	B (60)
Lenalidomide Myelodysplastic Syndrome With Excess Blasts	National Cancer Institute (NCI)	P2	B (60)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P2	B (59)
Rituximab Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P2	B (57)
Thiotepa Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P2	B (57)
Decitabine Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P2	CCC (53)
Enasidenib Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P2	CCC (53)
NK-92 Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P2	CCC (53)
Cpx-351 Myelodysplastic Syndrome With Excess Blasts	Ohio State University Comprehensive Cancer Center	P1/2	CCC (48)
Dilanubicel Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P2	CCC (48)
Filgrastim-Sndz Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P2	CCC (48)
Quizartinib Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P1/2	CCC (48)
Apamistamab-B10-Astatine At-211 Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P1/2	CC (47)
Recombinant Human Granulocyte Colony-Stimulating Factor Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P1/2	CC (47)
Apl-4098 Myelodysplastic Syndrome With Excess Blasts	Apollo Therapeutics Ltd	P1	CC (43)
Tak-243 Myelodysplastic Syndrome With Excess Blasts	National Cancer Institute (NCI)	P1	CC (43)
Venetoclax Myelodysplastic Syndrome With Excess Blasts	Apollo Therapeutics Ltd	P1	CC (43)